LinkedIn Profile

Access Xcovery historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:xcovery 647976 Apr 1st, 2020 12:00AM Xcovery 647 12.00 Open Biotechnology Apr 1st, 2020 04:41PM Apr 1st, 2020 04:41PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 30th, 2020 12:00AM Xcovery 647 12.00 Open Biotechnology Mar 29th, 2020 08:02PM Mar 30th, 2020 07:53PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 29th, 2020 12:00AM Xcovery 646 12.00 Open Biotechnology Mar 28th, 2020 08:13PM Mar 28th, 2020 08:13PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 28th, 2020 12:00AM Xcovery 646 12.00 Open Biotechnology Mar 27th, 2020 08:34PM Mar 27th, 2020 08:34PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 26th, 2020 12:00AM Xcovery 646 12.00 Open Biotechnology Mar 26th, 2020 07:30PM Mar 26th, 2020 07:30PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 25th, 2020 12:00AM Xcovery 646 12.00 Open Biotechnology Mar 25th, 2020 05:48PM Mar 25th, 2020 05:48PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 24th, 2020 12:00AM Xcovery 646 12.00 Open Biotechnology Mar 24th, 2020 02:26PM Mar 24th, 2020 02:26PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 23rd, 2020 12:00AM Xcovery 645 12.00 Open Biotechnology Mar 22nd, 2020 08:09PM Mar 23rd, 2020 07:24PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 22nd, 2020 12:00AM Xcovery 645 12.00 Open Biotechnology Mar 21st, 2020 11:06PM Mar 21st, 2020 11:06PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Mar 20th, 2020 12:00AM Xcovery 645 12.00 Open Biotechnology Mar 20th, 2020 02:34PM Mar 20th, 2020 02:34PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.